Peptides DB
Research-centric peptide and protocol reference hub
Study 40 of 41SS-31 literatureCirculation. Heart failure · RCT · PreclinicalHigh-impact journal2026

Targeting Mitochondrial Dysfunction With Elamipretide (SS-31) Improves Skeletal Muscle Performance in a HFpEF Rat Model.

Elamipretide treatment improved muscle performance in HFpEF rats, indicating a potential avenue for addressing exercise intolerance, but further research is needed to confirm these findings in humans.

Read at Circulation. Heart failureAdd to compare

Where it sits

this study against the rest of the ss-31 corpus
3
Preclinical
29
Observational
0
Open-label
4
Randomised · this one
5
Reviews

Summary and findings

This study measured the effects of Elamipretide on skeletal muscle performance in a heart failure with preserved ejection fraction (HFpEF) rat model. The treatment was administered for 12 weeks to HFpEF rats and compared to a control group receiving NaCl. Significant improvements in muscle contractile function and prevention of atrophy were observed with Elamipretide treatment.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
+173.2% single-fiber contractile function in soleus, p<0.001Preclinical2026

Abstract

The authors’ words, as Circulation. Heart failure supplied them

<h4>Background</h4>Exercise intolerance, promoted by skeletal muscle- and mitochondrial dysfunction, has been identified as a therapeutic target in heart failure with preserved ejection fraction (HFpEF). In the context of mitochondrial dysfunction, altered cardiolipin integrity has been reported in the myocardium of HFpEF, suggesting Elamipretide, a cardiolipin stabilizing agent, as potential therapeutic approach. The present study investigated cardiolipin dysregulation in the skeletal muscle of HFpEF rats and analyzed the effect of Elamipretide treatment.<h4>Methods</h4>Female zucker fatty spontaneously hypertensive heart failure F1 hybrid lean (n=10, control) and obese rats (n=24, HFpEF) were included. At 20 weeks of age, HFpEF rats were randomized into 2 groups receiving NaCl (n=12) or Elamipretide (n=12) for 12 weeks. Skeletal muscle tissue was collected for whole-muscle force, single-fiber mechanics, mitochondrial respiration, histology and molecular analyses.<h4>Results</h4>HFpEF rats exhibited reduced cardiolipin levels (-6.8%, <i>P</i>=0.007) and maturation (shown via tafazzin expression), contractile dysfunction, titin hyperphosphorylation, fiber atrophy and increased oxidative stress markers. Elamipretide improved whole muscle (soleus: +8.2%, <i>P</i>=0.041, extensor digitorum longus: +10.9%, <i>P</i>=0.016) and single-fiber (soleus: +173.2%, <i>P</i><0.001, extensor digitorum longus: +66.0%, <i>P</i>=ns) contractile function and titin phosphorylation (soleus: -35.4%, <i>P</i><0.001, extensor digitorum longus: -40.2%, <i>P</i><0.001), while preventing atrophy development (soleus: +49%, <i>P</i>=0.001, extensor digitorum longus: +54.8%, <i>P</i><0.001). Improved mitochondrial function, presumably through cardiolipin-mediated improvements in oxidative phosphorylation, could be associated with muscle force and cardiolipin integrity.<h4>Conclusions</h4>Our data highlight cardiolipin stabilization as a key modulator of mitochondrial and contractile function in HFpEF, identifying Elamipretide as a promising therapeutic approach for skeletal muscle dysfunction.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the SS-31 corpus

CMitochondrial dysfunction drives age-related degeneration of the thoracic aorta.GeroScience · 2026 · Not reported in abstract.AnimalCReversal of Mitochondrial Transhydrogenase Causes Oxidative Stress in Heart Failure.Cell metabolism · 2015 · Not reported in abstract.AnimalCNovel Role for Cardiolipin as a Target of Therapy to Mitigate Myocardial Injury Caused by Venoarterial Extracorporeal Membrane Oxygenation.Circulation · 2024 · Infarct size increased to 48±7% with VA-ECMO compared to 36±8% with reperfusion alone, P<0.001.AnimalCStructural and functional characterisation of the dextran utilisome from Bacteroides thetaiotaomicron.Journal of structural biology: X · 2026 · Not reported in abstract.In vitroC4-oxo-quinoline based fluorescent chemosensors for on-site detection of G-type nerve agent mimic DCP via spectroscopic and theoretical insights.Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy · 2026 · Limit of detection for DCP: 0.14 μM for 6DEQA.In vitroDEffectiveness of virtual reality-based rehabilitation on quality of life and upper extremity functions among stroke survivors: A systematic review and meta-analysis.International journal of nursing studies advances · 2026 · SMD = -0.09, 95% CI -0.30 to 0.11, p = .36; low certainty for QoL.review